Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past several shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire job interview which I came away with an inadequate impression of the company.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise and also connected intellectual property from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) along with the first new drug application approval ($five million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and numerous therapies, it has this single therapies and a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Can all this be smoke and mirrors? That’s a question I have been asking myself from the very beginning of my interest in this organization. Judging by way of the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *